Corey Goodman

The American Philosophical Society is an organization that hosts biannual general meetings for its members, families, and distinguished guests. The non-profit company is based in Philadelphia, PA. The meetings cater to the diverse interests and expertise of attendees and provide a unique opportunity to indulge the audience’s breadth of intellectual curiosity. The society has an exceptional collection of over 13 million manuscripts, objects, books, images, and works of art covering various topics such as early and revolutionary history, natural history, Indian linguistics and culture, nuclear physics, computer development, medical science, genetics and eugenics, and the development of cultural anthropology.

The McKnight Endowment Fund for Neuroscience operates as a philanthropic organization. Its services include grantmaking, coalition-building and encouragement of strategic policy reforms. The company was founded by William L. McKnight in 1989 and is headquartered in Minneapolis, MN.

Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

The National Research Council provides science, technology and health policy consulting and advice. The company was founded in 1916 and is headquartered in Washington, DC.

ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA.

NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL.

The California Council on Science & Technology is an organization that promotes the role of science in guiding the economy, society, and environment. The non-profit company is based in Riverside, CA. The company offers a Science and Technology Policy Fellowship program and have a list of alumni dating back to 2010.

venBio Partners LLC (venBio) is a venture capital subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.

Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA.

Labrys Biologics, Inc. provides biotechnology services. It is a venture-financed development stage biotechnology company, which focuses on treatments for chronic migraine. The company was founded by Corey S. Goodman in 2012 and is headquartered in San Francisco, CA.

Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA.

Avoro Capital Advisor LLC (AVCAP) is a SEC-registered investment advisor and hedge fund management subsidiary of Avoro Capital LP. The firm was founded by Corey Goodman in 2009 as venBio Select Advisor LLC. In 2019, a strategic transaction was closed whereby venBio Select Advisor LP entered into an agreement to sell its wholly-owned subsidiary, venBio Select Advisor LLC, the investment manager of the venBio Select Funds, to a newly-formed holding company, Avoro Capital LP. Headquartered in New York, AVCAP provides investment advice and management to privately placed investment funds and separately managed account for high net-worth individuals.

Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland.

Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX.

Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA.

Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA.

Axonis Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, committed to developing groundbreaking therapies for spinal cord injury and other currently incurable neurological disorders. The company is advancing two breakthrough discoveries, KCC2 upmodulation to reactivate spared tissue and PTEN inhibition to regenerate injured nerve connections, to make a real difference for patients, their families, and the healthcare system. The company was founded by Lisa McKerracher, Corey S. Goodman, Oswald Steward, Joanna Stanicka, Patrick J. Carew, Shane V. Hegarty, Bob Yant. Joanna Stanicka has been the CEO since incorporation.

Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA.